头皮脂溢性皮炎。

BMJ clinical evidence Pub Date : 2015-05-27
Luigi Naldi, Janouk Diphoorn
{"title":"头皮脂溢性皮炎。","authors":"Luigi Naldi, Janouk Diphoorn","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Seborrhoeic dermatitis affects a variable proportion of the general population, ranging from 3% to 10%. Malassezia yeast species (previously referred to as Pityrosporum) are thought to be the responsible organisms, and cause inflammation by still poorly defined mechanisms. Seborrhoeic dermatitis tends to relapse after treatment.</p><p><strong>Methods and outcomes: </strong>We conducted a systematic review and aimed to answer the following clinical question: What are the effects of topical treatments for seborrhoeic dermatitis of the scalp in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to November 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).</p><p><strong>Results: </strong>We found 14 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p><p><strong>Conclusions: </strong>In this systematic review we present information relating to the effectiveness and safety of the following interventions: bifonazole, ciclopirox, ketoconazole, pyrithione zinc, selenium sulfide, tar shampoo, terbinafine, and topical corticosteroids (betamethasone valerate, clobetasol propionate, clobetasone butyrate, hydrocortisone, mometasone furoate).</p>","PeriodicalId":72432,"journal":{"name":"BMJ clinical evidence","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445675/pdf/2015-1713.pdf","citationCount":"0","resultStr":"{\"title\":\"Seborrhoeic dermatitis of the scalp.\",\"authors\":\"Luigi Naldi, Janouk Diphoorn\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Seborrhoeic dermatitis affects a variable proportion of the general population, ranging from 3% to 10%. Malassezia yeast species (previously referred to as Pityrosporum) are thought to be the responsible organisms, and cause inflammation by still poorly defined mechanisms. Seborrhoeic dermatitis tends to relapse after treatment.</p><p><strong>Methods and outcomes: </strong>We conducted a systematic review and aimed to answer the following clinical question: What are the effects of topical treatments for seborrhoeic dermatitis of the scalp in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to November 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).</p><p><strong>Results: </strong>We found 14 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p><p><strong>Conclusions: </strong>In this systematic review we present information relating to the effectiveness and safety of the following interventions: bifonazole, ciclopirox, ketoconazole, pyrithione zinc, selenium sulfide, tar shampoo, terbinafine, and topical corticosteroids (betamethasone valerate, clobetasol propionate, clobetasone butyrate, hydrocortisone, mometasone furoate).</p>\",\"PeriodicalId\":72432,\"journal\":{\"name\":\"BMJ clinical evidence\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445675/pdf/2015-1713.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ clinical evidence\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ clinical evidence","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:脂溢性皮炎在普通人群中所占比例不等,从 3% 到 10% 不等。马拉色酵母菌(以前被称为Pityrosporum)被认为是致病菌,其引起炎症的机制尚不明确。脂溢性皮炎在治疗后往往会复发:我们进行了一项系统回顾,旨在回答以下临床问题:成人头皮脂溢性皮炎的局部治疗效果如何?我们检索了Medline、Embase、Cochrane 图书馆和其他重要数据库(截至 2013 年 11 月)(临床证据综述会定期更新;请在我们的网站上查看本综述的最新版本)。我们还纳入了美国食品药品管理局 (FDA) 和英国药品和保健品管理局 (MHRA) 等相关机构发布的危害警报:我们发现有 14 项研究符合纳入标准。我们对干预措施的证据质量进行了 GRADE 评估:在本系统综述中,我们介绍了与以下干预措施的有效性和安全性有关的信息:联苯苄唑、环吡酮胺、酮康唑、吡硫翁锌、硫化硒、焦油洗发水、特比萘芬和外用皮质类固醇激素(戊酸倍他米松、丙酸氯倍他索、丁酸氯倍他松、氢化可的松、糠酸莫米松)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Seborrhoeic dermatitis of the scalp.

Introduction: Seborrhoeic dermatitis affects a variable proportion of the general population, ranging from 3% to 10%. Malassezia yeast species (previously referred to as Pityrosporum) are thought to be the responsible organisms, and cause inflammation by still poorly defined mechanisms. Seborrhoeic dermatitis tends to relapse after treatment.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of topical treatments for seborrhoeic dermatitis of the scalp in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to November 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 14 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bifonazole, ciclopirox, ketoconazole, pyrithione zinc, selenium sulfide, tar shampoo, terbinafine, and topical corticosteroids (betamethasone valerate, clobetasol propionate, clobetasone butyrate, hydrocortisone, mometasone furoate).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信